Acute suppression of circulating sCD40L during hyperglycemia and euglycemic-hyperinsulinemia in healthy young males

Journal of Investigative Medicine

Volumn 56, Issue 7, 2008, Pages 902-910

  Oliver, Stacy R ^a   Flores, Rebecca L ^a   Pontello, Andria M ^a   Rosa, Jaime S ^a,b   Zaldivar, Frank P ^a   Galassetti, Pietro R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytokines; Healthy; Insulin; sCD40L; Young males

Indexed keywords

CD40 LIGAND; CYTOKINE; EOTAXIN; EPIDERMAL GROWTH FACTOR; FATTY ACID; GLUCOSE; HYDROCORTISONE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 9; KETONE; SOLUBLE CD40 LIGAND; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; LIPID;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATHETER; CLAMP; CYTOKINE PRODUCTION; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; HYPERINSULINEMIA; IMMUNOMODULATION; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN INFUSION; MALE; NORMAL HUMAN; OBESITY; BLOOD; GLUCOSE CLAMP TECHNIQUE; HYPERINSULINISM; IMMUNOLOGY; METABOLISM;

ADULT; BLOOD GLUCOSE; CD40 LIGAND; CYTOKINES; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; INFLAMMATION MEDIATORS; INSULIN; LIPIDS; MALE;

EID: 58149145531     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31818914e4     Document Type: Article

References (55)

1. Cancello R, Clement K. Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. BJOG. 2006;113(10): 1141-1147.
2. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-867.
3. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006; 444(7121):875-880.
4. Yu Y, Lyons TJ. A lethal tetrad in diabetes: hyperglycemia, dyslipidemia, oxidative stress, and endothelial dysfunction. Am J Med Sci. 2005;330(5):227-232.
5. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111(11):1448-1454.
6. Pereira FO, Frode TS, Medeiros YS. Evaluation of tumour necrosis factor alpha, interleukin-2 soluble receptor, nitric oxide metabolites, and lipids as inflammatory markers in type 2 diabetes mellitus. Mediators Inflamm. 2006;2006(1):39062.
7. Vincent HK, Taylor AG. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int J Obes (Lond). 2006;30(3):400-418.
8. Janowska J, Zahorska-Markiewicz B, Olszanecka-Glinianowicz M. Relationship between serum resistin concentration and proinflammatory cytokines in obese women with impaired and normal glucose tolerance. Metabolism. 2006;55(11): 1495-1499.
9. Warnberg J, Nova E, Moreno LA, et al. Inflammatory proteins are related to total and abdominal adiposity in a healthy adolescent population: the AVENA Study. Am J Clin Nutr. 2006;84(3):505-512.
10. Klebanova EM. Oxidative stress, the functional activity of beta-cells, and the content of tumor necrosis factor alpha in patients with type II diabetes mellitus. Klin Med (Mosk). 2006;84(8):40-43.
11. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391(6667):591-594.
12. Dechanet J, Grosset C, Taupin JL, et al. CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells. J Immunol. 1997;159(11):5640-5647.
13. Slupsky JR, Kalbas M, Willuweit A, et al. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost. 1998;80(6):1008-1014.
14. Zhou L, Stordeur P, de LA, et al. CD40 engagement on endothelial cells promotes tissue factor-dependent procoa-gulant activity. Thromb Haemost. 1998;79(5):1025-1028.
15. Anand SX, Viles-Gonzalez JF, Badimon JJ, et al. Membrane-associated CD40L and sCD40L in atherothrom-botic disease. Thromb Haemost. 2003;90(3):377-384.
16. Lobbes MB, Lutgens E, Heeneman S, et al. Is there more than C-reactive protein and fibrinogen? The prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease. Atherosclerosis. 2006;187(1): 18-25.
17. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348(12):1104-1111.
18. Tousoulis D, Antoniades C, Nikolopoulou A, et al. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes. Eur J Clin Invest. 2007;37(8):623-628.
19. Wang Y, Li L, Tan HW, et al. Transcoronary concentration gradient of sCD40L and hsCRP in patients with coronary heart disease. Clin Cardiol. 2007;30(2):86-91.
20. Schonbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104(19): 2266-2268.
21. Schernthaner GH, Kopp HP, Krzyzanowska K, et al. Soluble CD40L in patients with morbid obesity: significant reduction after bariatric surgery. Eur J Clin Invest. 2006; 36(6):395-401.
22. Guldiken S, Demir M, Arikan E, et al. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: soluble CD40 ligand and high-sensitivity C-reactive protein. Thromb Res. 2007;119(1):79-84.
23. Gokulakrishnan K, Deepa R, Mohan V, et al. Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome - the Chennai Urban Rural Epidemiology Study. Metabolism. 2006; 55(2):237-242.
24. Lee WL, Lee WJ, Chen YT, et al. The presence of metabolic syndrome is independently associated with elevated serum CD40 ligand and disease severity in patients with symptomatic coronary artery disease. Metabolism. 2006;55(8):1029-1034.
25. Harding SA, Sommerfield AJ, Sarma J, et al. Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus. Atherosclerosis. 2004; 176(2):321-325.
26. Devaraj S, Glaser N, Griffen S, et al. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes. 2006;55(3):774-779.
27. Katakami N, Kaneto H, Matsuhisa M, et al. Association of soluble CD40 ligand with carotid atherosclerosis in Japanese type 1 diabetic patients. Diabetologia. 2006; 49(7):1670-1676.
28. Yngen M, Ostenson CG, Hu H, et al. Enhanced P-selectin expression and increased soluble CD40 ligand in patients with type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation. Diabetologia. 2004;47(3):537-540.
29. Jinchuan Y, Zonggui W, Jinming C, et al. Upregulation of CD40-CD40 ligand system in patients with diabetes mellitus. Clin Chim Acta. 2004;339(1-2):85-90.
30. Santilli F, Davi G, Consoli A, et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol. 2006;47(2):391-397.
31. Varo N, Libby P, Nuzzo R, et al. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. Diab Vasc Dis Res. 2005;2(2):81-87.
32. Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation. 2004;109(21):2524-2528.
33. Vishnevetsky D, Kiyanista VA, Gandhi PJ. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann Pharmacother. 2004;38(9):1500-1508.
34. Galassetti PR, Iwanaga K, Pontello AM, et al. Effect of prior hyperglycemia on IL-6 responses to exercise in children with type 1 diabetes. Am J Physiol Endocrinol Metab. 2006;290(5):E833-E839.
35. Devaraj S, Venugopal SK, Singh U, et al. Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}. Diabetes. 2005; 54(1):85-91.
36. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106(16):2067-2072.
37. Sampson MJ, Gopaul N, Davies IR, et al. Plasma F2-isoprostanes - direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. Diabetes Care. 2002;25:537-541.
38. Evans JL, Goldfine ID, Maddux BA, et al. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23(5): 599-622.
39. Hansen AP, Johansen K. Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics. Diabetologia. 1970;6(1):27-33.
40. Bravi MC, Armiento A, Laurenti O, et al. Insulin decreases intracellular oxidative stress in patients with type 2 diabetes mellitus. Metabolism. 2006;55(5):691-695.
41. Vaidyula VR, Rao AK, Mozzoli M, et al. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes. 2006;55(1):202-208.
42. Vaidyula VR, Boden G, Rao AK. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets. 2006;17(8):577-585.
43. Lopes HF, Morrow JD, Stojiljkovic MP, et al. Acute hyperlipidemia increases oxidative stress more in African Americans than in white Americans. Am J Hypertens. 2003;16:331-336.
44. Stojiljkovic MP, Lopes HF, Zhang D, et al. Increasing plasma fatty acids elevates F2-isoprostanes in humans: implications for the cardiovascular risk factor cluster. J Hypertens. 2002;20:1215-1221.
45. Oguogho A, Ferlitsch A, Sinzinger H. LDL-apheresis decreases plasma levels and urinary excretion of 8-epi-PGF2alpha. Prostaglandins Leukot Essent Fatty Acids. 2000;62(4):209-216.
46. Viardot A, Grey ST, Mackay F, et al. Potential antiin-flammatory role of insulin via the preferential polarization of effector T cells toward a T helper 2 phenotype. Endocrinology. 2007;148(1):346-353.
47. Aljada A, Ghanim H, Saadeh R, et al. Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab. 2001;86(1): 450-453.
48. Hansen TK, Thiel S, Wouters PJ, et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab. 2003;88(3): 1082-1088.
49. Rosa JS, Oliver SR, Flores RL, Graf SC, Pontello AM, Ibardolaza M, Zaldivar FP, Galassetti PR. Kinetic profiles of 18 systemic pro- and anti-inflammatory mediators during and following exercise in children. J Pediatr Endocrinol Metab. In press 2008.
50. Rosa JS, Oliver SR, Mitsuhashi M, Flores RL, Pontello AM, Zaldivar FP, Galassetti PR. Altered kinetics of IL-6 and other inflammatory mediators during exercise in children with type 1 diabetes. J Investig Med. In press 2008.
51. Astaneie F, Afshari M, Mojtahedi A, et al. Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients. Arch Med Res. 2005;36(4):376-381.
52. Hong JP, Jung HD, Kim YW. Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers. Ann Plast Surg. 2006;56(4):394-398.
53. Miettinen PJ, Ustinov J, Ormio P, et al. Downregulation of EGF receptor signaling in pancreatic islets causes diabetes due to impaired postnatal beta-cell growth. Diabetes. 2006;55(12):3299-3308.
54. Suarez-Pinzon WL, Yan Y, Power R, et al. Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes. 2005;54(9):2596-2601.
55. Ivandic BT, Spanuth E, Haase D, et al. Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation. Clin Chem. 2007;53(7):1231-1234.